Valery Savchenko

List of Publications by Year
in descending order

109	863	759233 12	580821 25
papers	citations	h-index	g-index

150	150	150	1233
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bloodstream infections in different stage of reconstitution after first allogeneic hematopoietic stem cell transplantation. Oncogematologiya, 2022, 17, 121-134.	0.3	4
2	Use of eltrombopag in treatment programs for patients with aplastic anemia. Gematologiya I Transfuziologiya, 2022, 67, 29-40.	0.6	0
3	Structure and prognostic signifi cance of 13q14 deletion in chronic lymphocytic leukemia. Gematologiya I Transfuziologiya, 2022, 67, 75-89.	0.6	3
4	Cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: clinical significance and definitions. TransplantologiÃ¢, 2022, 14, 210-225.	0.4	2
5	Extracorporeal photopheresis in the treatment of chronic graft-versus-host-disease. Gematologiya I Transfuziologiya, 2022, 67, 202-215.	0.6	0
6	Comparison of polymerase chain reaction and flow cytometry for measuring telomere length of human leukocytes. Klinicheskeskaya Laboratornaya Diagnostika, 2021, 66, 154-159.	0.5	1
7	Experience of haematological observatory ward during COVID-10 pandemic. Gematologiya I Transfuziologiya, 2021, 66, 8-19.	0.6	1
8	Liâ€“Fraumeni syndrome in adult patients with acute lymphoblastic leukemia. Terapevticheskii Arkhiv, 2021, 93, 763-769.	0.8	0
9	Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects. Terapevticheskii Arkhiv, 2021, 93, 753-762.	0.8	0
10	Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report. Terapevticheskii Arkhiv, 2021, 93, 793-799.	0.8	0
11	Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease. Bulletin of Experimental Biology and Medicine, 2021, 171, 553-558.	0.8	1
12	Next generation sequencing HLA-typing of recipients and donors of allogeneic haematopoietic stem cells. Gematologiya I Transfuziologiya, 2021, 66, 206-217.	0.6	1
13	Risk-adapted combined therapy with arsenic trioxide and all-trans-retinoic acid for de novo acute promyelocytic leuÐºaemia. Gematologiya I Transfuziologiya, 2021, 66, 168-191.	0.6	2
14	Minimal residual disease and b-cell subpopulation monitoring in acute b-lymphoblastic leukaemia patients treated on rall-2016 protocol. Gematologiya I Transfuziologiya, 2021, 66, 192-205.	0.6	4
15	Comparative assessment of efficacy and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in the treatment of patients with diffuse large B-cell lymphoma with poor prognostic factors in a randomized multicenter clinical trial â€œDLBCL-2015â€• Oncogematologiya, 2021, 16, 86-94.	0.3	2
16	Contribution of social and demographic parameters to the long-term survival prognosis of chronic myeloid leukemia patients. Gematologiya I Transfuziologiya, 2021, 66, 346-361.	0.6	1
17	The effect of cryopreservation on the parameters of mononuclear apoptosis during extracorporeal photopheresis. Gematologiya I Transfuziologiya, 2021, 66, 386-394.	0.6	0
18	Minor histocompatibility antigens as targets for T-cell immunotherapy. Gematologiya I Transfuziologiya, 2021, 66, 322-345.	0.6	1

#	Article	IF	Citations
19	Prognostic value of minimal residual disease before allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. Gematologiya I Transfuziologiya, 2021, 66, 539-555.	0.6	0
20	Regional hematology service registration system for the Russian Federation. Gematologiya I Transfuziologiya, 2021, 66, 610-621.	0.6	1
21	Analysis of Bone Tissue Condition in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement. Bulletin of Experimental Biology and Medicine, 2020, 169, 677-682.	0.8	0
22	Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry. Blood, 2020, 136, 41-42.	1.4	3
23	Clinical guidelines for cryoprecipitate transfusions. Gematologiya I Transfuziologiya, 2020, 65, 87-114.	0.6	6
24	Clinical guidelines for cryosupernatant transfusions. Gematologiya I Transfuziologiya, 2020, 65, 351-359.	0.6	1
25	Outbreak of mass poisoning with anticoagulant rodenticides. Gematologiya I Transfuziologiya, 2020, 65, 174-189.	0.6	5
26	Clinical recommendations for the diagnosis and treatment of aplastic anemia (2019 edition). Gematologiya I Transfuziologiya, 2020, 65, 208-226.	0.6	9
27	Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia. Gematologiya I Transfuziologiya, 2020, 65, 444-459.	0.6	2
28	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. Gematologiya I Transfuziologiya, 2020, 65, 370-385.	0.6	3
29	Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. Oncogematologiya, 2020, 15, 18-28.	0.3	0
30	Oligoclonality and subpopulation structure of bone marrow T-cells in patients with aplastic anaemia. Gematologiya I Transfuziologiya, 2020, 65, 417-430.	0.6	1
31	First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the TP53 gene. Gematologiya I Transfuziologiya, 2020, 65, 483-500.	0.6	1
32	Reconstitution of T-cell-mediated immunity in patients after allogeneic stem cell transplantation. Gematologiya I Transfuziologiya, 2020, 65, 24-38.	0.6	4
33	Implementation of allogeneic hematopoietic stem cell transplantation from unrelated donors from Russian and foreign registries. Gematologiya I Transfuziologiya, 2020, 65, 299-311.	0.6	3
34	The role of interleukin-3 and its receptor in acute leukemia pathogenesis. Gematologiya I Transfuziologiya, 2020, 65, 335-350.	0.6	0
35	Bone Marrow Multipotent Mesenchymal Stromal Cells in Patients with Diffuse Large B-Cell Lymphoma. Bulletin of Experimental Biology and Medicine, 2019, 167, 150-153.	0.8	11
36	Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation. Oncogematologiya, 2019, 14, 76-82.	0.3	1

#	Article	IF	Citations
37	PROVISION OF CENTRAL VENOUS ACCESS DURING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. Gematologiya I Transfuziologiya, 2019, 64, 396-411.	0.6	1
38	Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry. Oncogematologiya, 2019, 13, 75-88.	0.3	0
39	Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients. Oncogematologiya, 2019, 13, 46-53.	0.3	1
40	Infectious Complications in Multiple Myeloma Patients Receiving Various Antitumor Regimens. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 131-139.	0.4	1
41	Gray-zone lymphoma. Examples of rare clinical manifestation. Terapevticheskii Arkhiv, 2019, 91, 107-113.	0.8	0
42	Subpopulations of mobilized hematopoietic stem cells in patients with hematological malignances and donors: expression of CD38, HLA-DR and CD143. Oncogematologiya, 2019, 14, 48-58.	0.3	0
43	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. Gematologiya I Transfuziologiya, 2019, 64, 35-48.	0.6	1
44	Detection of platelet-associated immunoglobulins and complement system components in patients with aplastic anemia and hemoblastosis. Oncogematologiya, 2019, 14, 38-51.	0.3	0
45	HIGH-DOSE CHEMOTHERAPY FOR PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. INTERIM RESULTS OF THE CNS-2015 PROTOCOL. Gematologiya I Transfuziologiya, 2019, 64, 447-461.	0.6	4
46	NELARABINE TREATMENT IN ADULT PATIENTS WITH REFRACTORY/ RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA: EXPERIENCE OF A SINGLE CENTRE. Gematologiya I Transfuziologiya, 2019, 64, 382-395.	0.6	0
47	Co-Culturing of Multipotent Mesenchymal Stromal Cells with Autological and Allogenic Lymphocytes. Bulletin of Experimental Biology and Medicine, 2018, 164, 446-452.	0.8	0
48	Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells. Stem Cells International, 2018, 2018, 1-7.	2.5	9
49	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 in Northern Ossetians from Vladikavkaz, Russia. Human Immunology, 2018, 79, 709-710.	2.4	1
50	Individual Differences of Multipotent Mesenchymal Stromal Cells Manifesting in during Interaction with Lymphocytes. Bulletin of Experimental Biology and Medicine, 2018, 165, 584-588.	0.8	1
51	Infectious complications in patients with multiple myeloma on first chemotherapy cycle. Oncogematologiya, 2018, 13, 63-75.	0.3	1
52	Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases. Terapevticheskii Arkhiv, 2018, 90, 110-117.	0.8	2
53	Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation. Terapevticheskii Arkhiv, 2018, 90, 14-22.	0.8	3
54	Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Terapevticheskii Arkhiv, 2018, 90, 23-29.	0.8	4

#	Article	IF	Citations
55	Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma. Terapevticheskii Arkhiv, 2018, 90, 51-56.	0.8	1
56	EXPRESSION FEATURES OF ANTIGENS INVOLVED IN THE FORMATION OF IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA. Oncogematologiya, 2018, 13, 103-114.	0.3	2
57	IMPACT OF HLA-DPB1 INCOMPATIBILITY ON THE RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM HLA-A-B-Câ€“DRB1-DQB1-COMPATIBLE UNRELATED DONOR. Oncogematologiya, 2018, 13, 54-62.	0.3	1
58	Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia. Terapevticheskii Arkhiv, 2018, 90, 30-37.	0.8	4
59	First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature. Terapevticheskii Arkhiv, 2018, 90, 77-81.	0.8	2
60	MORPHOLOGICAL FEATURES OF TUMORS SUBSTRATE IN MULTIPLE MYELOMA PATIENTS COMPLICATED WITH PLASMACYTOMA. Oncogematologiya, 2018, 13, 73-81.	0.3	4
61	Infectious complications in patients with acute leukemia according to the duration of neutropenia. Oncogematologiya, 2018, 13, 55-62.	0.3	2
62	Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol). Oncogematologiya, 2018, 13, 10-24.	0.3	2
63	Successful experience in treating primary cutaneous anaplastic large cell lymphoma occuring with common lesions of the skin and lung tissue. Vestnik Dermatologii I Venerologii, 2018, 94, 30-42.	0.6	0
64	Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2017, 58, 408-417.	1.3	11
65	Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute Graft-versus-host disease after day +30 after allo-HSCT. Leukemia Research, 2017, 54, 25-29.	0.8	7
66	Effect of priming of multipotent mesenchymal stromal cells with interferon Î³ on their immunomodulating properties. Biochemistry (Moscow), 2017, 82, 1158-1168.	1.5	9
67	Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNÎ³ Administration. Bulletin of Experimental Biology and Medicine, 2017, 163, 230-234.	0.8	11
68	CDKN2A/p16INK4a DELETION IS NOT A POOR PROGNOSTIC FACTOR IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED ACCORDING TO PROTOCOL RALL-2009. Oncogematologiya, 2017, 12, 17-24.	0.3	4
69	INFECTIONS ON DIFFERENT CHEMOTHERAPY CYCLES IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH ALL-2009 PROTOCOL. Oncogematologiya, 2017, 12, 31-40.	0.3	3
70	SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT. Oncogematologiya, 2017, 12, 23-29.	0.3	0
71	STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Oncogematologiya, 2017, 12, 62-69.	0.3	2
72	The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells. European Journal of Haematology, 2016, 97, 245-252.	2.2	8

#	Article	IF	Citations
73	Recombinant MHC tetramers for isolation of virus-specific CD8+ cells from healthy donors: Potential approach for cell therapy of posttransplant cytomegalovirus infection. Biochemistry (Moscow), 2016, 81, 1371-1383.	1.5	8
74	Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure. International Journal of Hematology, 2016, 104, 403-407.	1.6	3
75	Human Herpesvirus Type 8-positive Multicentric Castleman Disease. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S159-S165.	0.4	5
76	A Single-center Experience in Splenic Diffuse Red Pulp Lymphoma Diagnosis. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S166-S169.	0.4	7
77	Analysis of multipotent mesenchymal stromal cells used for acute graftâ€versusâ€host disease prophylaxis. European Journal of Haematology, 2016, 96, 425-434.	2.2	11
78	Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. Leukemia, 2016, 30, 104-111.	7.2	54
79	IMMUNOBIOLOGY OF ACUTE GRAFT-VERSUS-HOST DISEASE. Medical Immunology (Russia), 2016, 17, 499-516.	0.4	6
80	Clonal CD57+ Cells in T-Cell Large Granular Lymphocytic Leukemia. Blood, 2016, 128, 4904-4904.	1.4	0
81	Identification of a novel alleleHLA-C*12:138in Russian patient by haplotype-specific sequence-based typing. Tissue Antigens, 2015, 85, 513-514.	1.0	4
82	Cytokine-mediated induction of MHC class II in human neutrophils is dependent on NADPH oxidase activity. European Journal of Cell Biology, 2015, 94, 67-70.	3.6	14
83	MYD88 L265P Mutation Is a Possible Unfavorable Prognostic Factor in Patients with Diffuse B-Cell Lymphoma. Blood, 2015, 126, 5051-5051.	1.4	2
84	Combination of arsenicum trioxide and all trans retinoic acid in the treatment of relapsed acute promyelocytic leukemia. Oncogematologiya, 2015, 10, 8.	0.3	1
85	Multiple Clonal TCR Gene Rearrangements Are Typical in Peripheral T-Cell Lymphoma Not Otherwise Specified. Blood, 2015, 126, 5036-5036.	1.4	0
86	Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochemistry (Moscow), 2014, 79, 1363-1370.	1.5	22
87	Neutrophil microparticles modulate cytokine production by natural killer cells. Cytokine, 2014, 65, 126-129.	3.2	43
88	Extracellular NAD+ inhibits human neutrophil apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 581-593.	4.9	17
89	Diadenosine diphosphate (Ap2A) delays neutrophil apoptosis via the adenosine A2A receptor and cAMP/PKA pathway. Biochemistry and Cell Biology, 2014, 92, 420-424.	2.0	8
90	Detection of B-Cell Clonality in Bone Marrow Is Independent Predictor of Outcome in De Novo Diffuse Large B-Cell Lymphoma Patients Treated with High-Dose Chemotherapy. Blood, 2014, 124, 2967-2967.	1.4	0

#	Article	IF	Citations
91	Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Diseaseâ€"A Phase II Study. Stem Cells International, 2012, 2012, 1-8.	2.5	98
92	Analysis of Expression of Genes Involved in Immune Response Modulation in Silent Multipotent Mesenchymal Stromal Cells. Bulletin of Experimental Biology and Medicine, 2012, 153, 244-248.	0.8	0
93	Hepatitis B and Hepatitis C Co-Infection in Patients with Hematological Malignancies. Blood, 2011, 118, 2090-2090.	1.4	0
94	A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 801-808.	2.0	30
95	Delayed effects of long-term administration of granulocyte colony-stimulating factor to mice. Bulletin of Experimental Biology and Medicine, 2008, 145, 629-633.	0.8	2
96	Vascular endothelium: target or victim of cytostatic therapy?This paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 396-403.	1.4	8
97	Genetic differences by platelet-specific antigens used for monitoring allomyelotransplant engraftment. Bulletin of Experimental Biology and Medicine, 2006, 141, 507-512.	0.8	1
98	Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. Bulletin of Experimental Biology and Medicine, 2006, 142, 527-530.	0.8	11
99	Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. Cancer Genetics and Cytogenetics, 2006, 167, 47-50.	1.0	5
100	Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment. Experimental Hematology, 2004, 32, 563-570.	0.4	3
101	Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Experimental Hematology, 2003, 31, 1301-1309.	0.4	81
102	Induction of Mixed Chimerism in Patients After Non-Myeloablative Stem Cell Transplantation (SCT) for High Risk Haematological Malignancies. Hamatologie Und Bluttransfusion, 2003, , 514-519.	0.0	1
103	The CD68 protein as a potential target for leukaemia-reactive CTL. Leukemia, 2002, 16, 2019-2026.	7.2	14
104	Production of granulocytic colony-stimulating factor in patients with chronic myeloleukemia. Bulletin of Experimental Biology and Medicine, 1998, 126, 724-727.	0.8	0
105	Flt3-ligand production by human bone marrow stromal cells. Leukemia, 1996, 10, 1012-8.	7.2	82
106	Evaluation of graft-versus-host disease based on measurement of HLA levels in the plasma of allogeneic bone marrow recipients. Bulletin of Experimental Biology and Medicine, 1995, 120, 1211-1213.	0.8	0
107	Defect of Stromal Microenvironment in Long Term Bone Marrow Cultures of Patients with Acute and Chronic Myelogenous Leukemias. Leukemia and Lymphoma, 1995, 19, 145-152.	1.3	10
108	Determination of serum antiplatelet antibodies in patients with idiopathic thrombocytopenic purpura by ELISA. Bulletin of Experimental Biology and Medicine, 1989, 107, 359-361.	0.8	2

#	Article	IF	Citations
109	Differences in Protein Secretion by Multipotent Mesenchymal Stromal Cells Effective and Ineffective in the Prevention of Acute Graftâ€"Versusâ€"Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Bulletin of Experimental Biology and Medicine, 0, , .	0.8	0